| scholarly article | Q13442814 |
| P50 | author | Eric Senneville | Q57045521 |
| Laurence Legout | Q114902581 | ||
| P2093 | author name string | Olivier Leroy | |
| Stephan Haulon | |||
| Piervito D'Elia | |||
| Nicolas Ettahar | |||
| Beatrice Sarraz-Bournet | |||
| P2860 | cites work | Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus | Q34073487 |
| Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus | Q34558111 | ||
| Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects | Q34882125 | ||
| Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers | Q35091557 | ||
| A systematic review and meta-analysis of treatments for aortic graft infection | Q36530692 | ||
| Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin | Q37247663 | ||
| Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis | Q37333049 | ||
| Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program | Q37509110 | ||
| Bacteremic infectability of vascular grafts: the influence of pseudointimal integrity and duration of graft function | Q39739713 | ||
| Bacteremic infectability: A function of vascular graft material and design | Q39812379 | ||
| Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus. | Q42112490 | ||
| Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations | Q42445383 | ||
| Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus | Q42529961 | ||
| Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy | Q42708842 | ||
| Daptomycin and rifampin alone and in combination prevent vascular graft biofilm formation and emergence of antibiotic resistance in a subcutaneous rat pouch model of staphylococcal infection. | Q42876968 | ||
| High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis | Q43443557 | ||
| Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans | Q43796988 | ||
| Aortic and peripheral prosthetic graft infection: differential management and causes of mortality | Q44642347 | ||
| Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin | Q46187290 | ||
| Daptomycin resistance in Enterococcus faecalis prosthetic valve endocarditis | Q46698667 | ||
| Rhabdomyolysis and acute renal failure in a patient treated with daptomycin | Q46892799 | ||
| The Relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population: a retrospective analysis | Q48594054 | ||
| Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices. | Q51143039 | ||
| Diagnosis and treatment of prosthetic aortic graft infections: confusion and inconsistency in the absence of evidence or consensus. | Q51325750 | ||
| Characteristics and prognosis in patients with prosthetic vascular graft infection: a prospective observational cohort study | Q57554410 | ||
| Rhabdomyolysis during therapy with daptomycin | Q83358521 | ||
| New MRSA guidelines highlight a dearth of evidence | Q83523490 | ||
| [Efficacy and safety of high dose (≥8 mg/kg/day) daptomycin] | Q83894977 | ||
| High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study | Q84954829 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 215-223 | |
| P577 | publication date | 2014-09-04 | |
| P1433 | published in | Infectious diseases and therapy | Q26842457 |
| P1476 | title | Tolerability of High Doses of Daptomycin in the Treatment of Prosthetic Vascular Graft Infection: A Retrospective Study | |
| P478 | volume | 3 |
| Q35802607 | Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORE(SM) Registry |
| Q36686882 | Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE. |
| Q52580415 | Statin Coadministration Increases the Risk of Daptomycin-Associated Myopathy. |
| Q38666387 | Vascular Graft Impregnation with Antibiotics: The Influence of High Concentrations of Rifampin, Vancomycin, Daptomycin, and Bacteriophage Endolysin HY-133 on Viability of Vascular Cells. |
Search more.